EFFECTS OF EXTRACORPOREAL CYTOKINE ELIMINATION ON HEMODYNAMIA AND MORTALITY IN CRITICAL PATIENTS
NCT ID: NCT05984407
Last Updated: 2023-08-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
30 participants
OBSERVATIONAL
2023-08-01
2024-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness of the Cytokine Hemadsorption on Sepsis
NCT05057455
Thromboembolic Complications in COVID-19 Patients in Intensive Care Unit
NCT06037707
Epidemiology and Determinants of Outcomes of Hospital Acquired Blood Stream Infections in the Intensive Care in Turkey
NCT04304456
Arterial and End-Tidal CO2 Gradient as a Mortality Predictor in Critical Care Patients
NCT05341258
ICU Mortality Predictors of Trauma Patients
NCT03894111
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patients with vasoplegic shock
Application of cytokine hemadsorption therapy in patients with vasoplegic shock without microbiological findings
cytokine hemadsorption therapy
Observation of cytokine hemadsorption therapy in critically ill patients who have no microbiological findings and develop vasoplegic shock.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
cytokine hemadsorption therapy
Observation of cytokine hemadsorption therapy in critically ill patients who have no microbiological findings and develop vasoplegic shock.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Procalcitonin (PCT) \< 2 ng/l
* Patients aged 18-80 years who were treated with cytokine adsorption due to vasoplegic shock
Exclusion Criteria
* Patients with suspected or proven bacterial cause of vasoplegic shock.
* Those who did not approve to participate in the study
* Patients without vasoplegic shock
* Patients with CRP \< 100 mg/l, PCT ≥ 2 μg/L
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hakan Küçükkepeci
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hakan Küçükkepeci
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Prof. Dr. Cemil Taşcıoğlu City Hospital
Istanbul, Şişli, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
652779
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.